1998
Invasion of the bladder by transitional cell carcinoma
Vollmer R, Humphrey P, Swanson P, Wick M, Hudson M. Invasion of the bladder by transitional cell carcinoma. Cancer 1998, 82: 715-723. PMID: 9477105, DOI: 10.1002/(sici)1097-0142(19980215)82:4<715::aid-cncr15>3.0.co;2-0.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Transitional CellEpidermal Growth FactorHumansImmunoenzyme TechniquesKi-67 AntigenLogistic ModelsNeoplasm InvasivenessNeoplasm ProteinsNeoplasm StagingPrognosisProspective StudiesProto-Oncogene Proteins c-bcl-2Receptor, ErbB-2Tumor Suppressor Protein p53Urinary Bladder NeoplasmsConceptsC-erb BTransitional cell carcinomaEpidermal growth factor receptorGrade 3 tumorsHistologic gradeMIB-1Cell carcinomaBcl-2Prognostic informationMultivariate logistic regression modelGrade 2 tumorsLogistic regression modelsWorld Health OrganizationGrowth factor receptorCombination of markersPrognostic factorsClinical outcomesProspective studyImmunohistochemical stainingPathologic levelsProtective effectLevel of invasionGrade 2Multivariate analysisCarcinoma
1994
Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Marks J, Humphrey P, Wu K, Berry D, Bandarenko N, Kerns B, Iglehart J. Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. Annals Of Surgery 1994, 219: 332-341. PMID: 7909221, PMCID: PMC1243148, DOI: 10.1097/00000658-199404000-00002.Peer-Reviewed Original ResearchConceptsHER-2/neuEarly-stage breast cancerStage breast cancerHER-2/neu oncogeneBreast cancerPrognostic valueHER-2/neu proteinNeu oncogeneGenetic abnormalitiesDuke University Medical CenterFailure-free survivalProgesterone receptor contentCohort of patientsLimited prognostic valueIndependent prognostic valueShorter survival timeParaffin-embedded specimensUniversity Medical CenterHER-2/neu geneOverexpression of p53Common genetic abnormalityNodal statusRetrospective cohortLow estrogenTumor size
1991
Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function
Humphrey P, Gangarosa L, Wong A, Archer G, Lund-Johansen M, Bjerkvig R, Laerum O, Friedman H, Bigner D. Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function. Biochemical And Biophysical Research Communications 1991, 178: 1413-1420. PMID: 1678600, DOI: 10.1016/0006-291x(91)91051-d.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBase SequenceCell LineChromosome DeletionEpidermal Growth FactorErbB ReceptorsGene AmplificationGene RearrangementGliomaHumansKineticsMolecular Sequence DataPhosphorylationProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsProto-OncogenesReceptor, ErbB-2Transforming Growth Factor alphaConceptsEGFR kinase activityMutant EGFRDeletion-mutant epidermal growth factor receptorGrowth factor receptor geneMutant EGFR proteinEpidermal growth factor receptorGrowth factorFactor receptor geneEpidermal growth factor receptor (EGFR) geneGrowth factor receptorKinase activityExtracellular domainGlioma cell proliferationDomain IVFrame deletionType II mutationAmino acidsEGFR proteinFactor receptorReceptor geneThree-dimensional spheroid modelCell proliferationReceptor functionEGFHuman gliomas